Details for New Drug Application (NDA): 020908
✉ Email this page to a colleague
The generic ingredient in VAGIFEM is estradiol. There are seventy-five drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the estradiol profile page.
Summary for 020908
Tradename: | VAGIFEM |
Applicant: | Novo Nordisk Inc |
Ingredient: | estradiol |
Patents: | 0 |
Pharmacology for NDA: 020908
Mechanism of Action | Estrogen Receptor Agonists |
Medical Subject Heading (MeSH) Categories for 020908
Suppliers and Packaging for NDA: 020908
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
VAGIFEM | estradiol | TABLET;VAGINAL | 020908 | NDA | Novo Nordisk | 0169-5176 | 0169-5176-03 | 8 APPLICATOR in 1 CARTON (0169-5176-03) / 1 INSERT in 1 APPLICATOR |
VAGIFEM | estradiol | TABLET;VAGINAL | 020908 | NDA | Novo Nordisk | 0169-5176 | 0169-5176-04 | 18 APPLICATOR in 1 CARTON (0169-5176-04) / 1 INSERT in 1 APPLICATOR |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;VAGINAL | Strength | 25MCG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Mar 26, 1999 | TE: | RLD: | Yes |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;VAGINAL | Strength | 10MCG | ||||
Approval Date: | Nov 25, 2009 | TE: | AB | RLD: | Yes |
Expired US Patents for NDA 020908
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novo Nordisk Inc | VAGIFEM | estradiol | TABLET;VAGINAL | 020908-002 | Nov 25, 2009 | ⤷ Sign Up | ⤷ Sign Up |
Novo Nordisk Inc | VAGIFEM | estradiol | TABLET;VAGINAL | 020908-002 | Nov 25, 2009 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription